HighTower Advisors LLC Purchases 565 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

HighTower Advisors LLC grew its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 34.0% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,227 shares of the medical research company’s stock after purchasing an additional 565 shares during the quarter. HighTower Advisors LLC’s holdings in Bio-Rad Laboratories were worth $1,265,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also modified their holdings of BIO. BlackRock Inc. grew its position in Bio-Rad Laboratories by 1.0% during the first quarter. BlackRock Inc. now owns 1,910,883 shares of the medical research company’s stock valued at $1,091,437,000 after buying an additional 18,547 shares during the period. FMR LLC boosted its stake in shares of Bio-Rad Laboratories by 20.5% during the 4th quarter. FMR LLC now owns 1,692,254 shares of the medical research company’s stock worth $986,483,000 after acquiring an additional 287,827 shares during the last quarter. UBS Asset Management Americas Inc. grew its position in shares of Bio-Rad Laboratories by 30.4% during the 4th quarter. UBS Asset Management Americas Inc. now owns 503,557 shares of the medical research company’s stock valued at $293,544,000 after acquiring an additional 117,413 shares during the period. Brown Advisory Inc. increased its stake in shares of Bio-Rad Laboratories by 2.2% in the 4th quarter. Brown Advisory Inc. now owns 475,672 shares of the medical research company’s stock worth $277,289,000 after purchasing an additional 10,263 shares in the last quarter. Finally, Alliancebernstein L.P. raised its holdings in Bio-Rad Laboratories by 20.4% in the 1st quarter. Alliancebernstein L.P. now owns 466,361 shares of the medical research company’s stock worth $266,371,000 after purchasing an additional 79,174 shares during the period. Hedge funds and other institutional investors own 65.18% of the company’s stock.

Shares of NYSE BIO opened at $602.97 on Friday. The stock has a market capitalization of $17.95 billion, a PE ratio of 4.43 and a beta of 0.83. Bio-Rad Laboratories, Inc. has a 1 year low of $425.43 and a 1 year high of $689.00. The stock has a fifty day moving average price of $604.41.

Bio-Rad Laboratories (NYSE:BIO) last issued its quarterly earnings results on Thursday, April 29th. The medical research company reported $5.21 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.50 by $2.71. Bio-Rad Laboratories had a return on equity of 4.55% and a net margin of 151.73%. The business had revenue of $726.80 million during the quarter, compared to analyst estimates of $661.00 million. On average, analysts forecast that Bio-Rad Laboratories, Inc. will post 12.07 earnings per share for the current year.

Separately, Citigroup upped their price target on Bio-Rad Laboratories from $675.00 to $750.00 and gave the stock a “buy” rating in a research report on Friday, February 12th.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc develops, manufactures, and markets life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components.

See Also: What Is an EV Stock

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.